Cargando…
Denosumab Induced Severe Hypocalcemia in a Patient With Metastatic Prostate Cancer
Background: Denosumab can lead to severe hypocalcemia in patients with underlying risk factors such as vitamin D deficiency, low PTH, hypomagnesemia, and CKD. Denosumab is a monoclonal antibody against RANKL, reducing the activity of osteoclasts and thus reducing the release of calcium in the bloods...
Autores principales: | Naher, Kamrun, Thrupthi, Komandur, Samsuddoha, Kazi, Galiveeti, Sneha, Leung, Vivien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090016/ http://dx.doi.org/10.1210/jendso/bvab048.384 |
Ejemplares similares
-
Denosumab Induced Severe Prolonged Hypocalcemia in Metastatic Prostate Cancer
por: Mehmood, Hassan, et al.
Publicado: (2021) -
SAT-512 Severe Hypocalcemia Presenting as Status Epilepticus after Denosumab Use in Metastatic Prostate Cancer
por: Saeed, Zeb, et al.
Publicado: (2019) -
Prolonged Hypocalcemia After a Single Dose of Denosumab in Chronic Kidney Disease
por: Puar, Akshan, et al.
Publicado: (2021) -
SAT-365 Severe, Symptomatic Hypocalcemia Due to Denosumab and Vitamin D Deficiency in an Osteopenic Post-Menopausal Female
por: Berquist, John, et al.
Publicado: (2020) -
PSAT189 Severe Hypocalcemia and Hypophosphatemia Associated with Denosumab use in a Chronic Myeloid Leukemia Patient on Imatinib
por: Shah, Tanvi, et al.
Publicado: (2022)